2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more
2Seventy Bio Inc (TSVT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: -0.051x
Based on the latest financial reports, 2Seventy Bio Inc (TSVT) has a cash flow conversion efficiency ratio of -0.051x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.97 Million) by net assets ($213.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
2Seventy Bio Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how 2Seventy Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
2Seventy Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 2Seventy Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CK Life Sciences Int'l. (Holdings) Inc
F:LSI
|
0.011x |
|
Shenzhen Wongtee International Enterprise Co Ltd
SHE:000056
|
-0.028x |
|
Lintes Technology Co Ltd
TW:6715
|
-0.007x |
|
Wuxi Xinhongye Wire & Cable Co. Ltd. A
SHE:301310
|
N/A |
|
Beijing Changjiu Logistics Ltd
SHG:603569
|
-0.012x |
|
Movida Participações S.A
SA:MOVI3
|
0.329x |
|
Nanjing Panda Electronics Company Limited
F:NNJ
|
0.013x |
|
Penns Woods Bancorp Inc
NASDAQ:PWOD
|
0.000x |
Annual Cash Flow Conversion Efficiency for 2Seventy Bio Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of 2Seventy Bio Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $210.81 Million | $-85.00 Million | -0.403x | +38.31% |
| 2023-12-31 | $255.30 Million | $-166.86 Million | -0.654x | +14.43% |
| 2022-12-31 | $310.47 Million | $-237.13 Million | -0.764x | -32.75% |
| 2021-12-31 | $359.82 Million | $-207.03 Million | -0.575x | +36.66% |
| 2020-12-31 | $74.63 Million | $-67.79 Million | -0.908x | +80.91% |
| 2019-12-31 | $43.69 Million | $-207.96 Million | -4.760x | -- |